Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.54), $0.13 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $6.28 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.